Phase 2b trial found lysergic acid diethylamide reduces anxiety in generalized anxiety disorder, suggesting its potential as a treatment.
Treatment with a single dose of a pharmaceutical formulation of lysergic acid diethylamide (LSD) resulted in a dose‐dependent reduction in anxiety in individuals with generalized anxiety disorder (GAD), a Phase 2b study has found. The two highest of four tested dose strengths of the MM120 formulation demonstrated significant improvement relative to placebo.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: